Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Shevrin

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancerRobert Dreicer, David MacLean, Ajit Suri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancerSteven Attia, Jens Eickhoff, George Wilding, et al.
Future Oncology (London, England)|February 9, 2018
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPETScott C Flanders, Janet Kim, Samuel Wilson, et al.
The Prostate|May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without DocetaxelLauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
The New England Journal of Medicine|August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.
Urologic Oncology|March 26, 2013
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordanceDavid E Victorson, Penny S Brucker, Rita K Bode, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2014
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancerRobert Dreicer, David MacLean, Ajit Suri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2008
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancerSteven Attia, Jens Eickhoff, George Wilding, et al.
Future Oncology (London, England)|February 9, 2018
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPETScott C Flanders, Janet Kim, Samuel Wilson, et al.
The Prostate|May 10, 2022
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805Alicia K Morgans, Yu-Hui Chen, David F Jarrard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without DocetaxelLauren C Harshman, Yu-Hui Chen, Glenn Liu, et al.
The New England Journal of Medicine|August 6, 2015
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J Sweeney, Yu-Hui Chen, Michael Carducci, et al.
Urologic Oncology|March 26, 2013
Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordanceDavid E Victorson, Penny S Brucker, Rita K Bode, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)Rahul Aggarwal, Glenn Heller, David W Hillman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.
Pageof 2